Cargando…

In Silico Study and Pharmacological Evaluation of Eplerinone as an Anti-Alzheimer’s Drug in STZ-Induced Alzheimer’s Disease Model

[Image: see text] Alzheimer’s disease (AD) is the neurodegenerative disorder characterized by impairment of higher intellectual dysfunctions associated with changes in the cognitive, behavioral, and social activities. Aim of the study: The current study was designed to evaluate the potential of aldo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hira, Sundas, Saleem, Uzma, Anwar, Fareeha, Raza, Zohaib, Rehman, Atta Ur, Ahmad, Bashir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301577/
https://www.ncbi.nlm.nih.gov/pubmed/32566864
http://dx.doi.org/10.1021/acsomega.0c01381
_version_ 1783547719612104704
author Hira, Sundas
Saleem, Uzma
Anwar, Fareeha
Raza, Zohaib
Rehman, Atta Ur
Ahmad, Bashir
author_facet Hira, Sundas
Saleem, Uzma
Anwar, Fareeha
Raza, Zohaib
Rehman, Atta Ur
Ahmad, Bashir
author_sort Hira, Sundas
collection PubMed
description [Image: see text] Alzheimer’s disease (AD) is the neurodegenerative disorder characterized by impairment of higher intellectual dysfunctions associated with changes in the cognitive, behavioral, and social activities. Aim of the study: The current study was designed to evaluate the potential of aldosterone antagonist in the treatment of AD. Methodology: The study was conducted on albino mice of either sex (n = 60). Mice were subcategorized into six groups, each group having 10 mice. Group I—normal control (CMC 1 mL/kg), group II—diseased [streptozotocin (STZ), 3 mg/kg, intracerebroventricular (i.c.v.)], group III—standard (piracetam, 200 mg/kg, i.p.), and groups IV–VI designated as the treatment group (eplerinone at dose levels of 4, 8, and 16 mg/kg, orally), respectively. The study was carried out for 14 consecutive days. STZ was administered through the i.c.v. route on first and third days of the study for memory impairment. The molecular docking was performed to investigate the chemical behavior of compounds to inhibit the AChE. Anti-Alzheimer’s effect was assessed by using the behavioral paradigms such as passive avoidance, elevated plus maze, Morris water maze, open field, and balance beam. Various endogenous antioxidants such as SOD, GSH, nitrite, MDA, CAT, and AChE were identified in brain tissues of treated mice to assess the oxidative stress index. Biochemical markers for AD such as norepinephrine, dopamine, and serotonin, Aβ 1–40, Aβ 1–42, NF-κB, and tumor necrosis factor alpha were analyzed in brain tissues of mice. Expression of beta amyloid was observed by PCR. Results: The in silico study indicated the distinct mechanism of eplerinone to inhibit the AChE. The outcomes of the in vivo study manifested that eplerinone at the highest dose was found to be more effective in the treatment of AD. Conclusion: It may be concluded from the research work that eplerinone can be effective for cognitive improvement which proposes its therapeutic effect in many neurodegenerative disorders such as AD.
format Online
Article
Text
id pubmed-7301577
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-73015772020-06-19 In Silico Study and Pharmacological Evaluation of Eplerinone as an Anti-Alzheimer’s Drug in STZ-Induced Alzheimer’s Disease Model Hira, Sundas Saleem, Uzma Anwar, Fareeha Raza, Zohaib Rehman, Atta Ur Ahmad, Bashir ACS Omega [Image: see text] Alzheimer’s disease (AD) is the neurodegenerative disorder characterized by impairment of higher intellectual dysfunctions associated with changes in the cognitive, behavioral, and social activities. Aim of the study: The current study was designed to evaluate the potential of aldosterone antagonist in the treatment of AD. Methodology: The study was conducted on albino mice of either sex (n = 60). Mice were subcategorized into six groups, each group having 10 mice. Group I—normal control (CMC 1 mL/kg), group II—diseased [streptozotocin (STZ), 3 mg/kg, intracerebroventricular (i.c.v.)], group III—standard (piracetam, 200 mg/kg, i.p.), and groups IV–VI designated as the treatment group (eplerinone at dose levels of 4, 8, and 16 mg/kg, orally), respectively. The study was carried out for 14 consecutive days. STZ was administered through the i.c.v. route on first and third days of the study for memory impairment. The molecular docking was performed to investigate the chemical behavior of compounds to inhibit the AChE. Anti-Alzheimer’s effect was assessed by using the behavioral paradigms such as passive avoidance, elevated plus maze, Morris water maze, open field, and balance beam. Various endogenous antioxidants such as SOD, GSH, nitrite, MDA, CAT, and AChE were identified in brain tissues of treated mice to assess the oxidative stress index. Biochemical markers for AD such as norepinephrine, dopamine, and serotonin, Aβ 1–40, Aβ 1–42, NF-κB, and tumor necrosis factor alpha were analyzed in brain tissues of mice. Expression of beta amyloid was observed by PCR. Results: The in silico study indicated the distinct mechanism of eplerinone to inhibit the AChE. The outcomes of the in vivo study manifested that eplerinone at the highest dose was found to be more effective in the treatment of AD. Conclusion: It may be concluded from the research work that eplerinone can be effective for cognitive improvement which proposes its therapeutic effect in many neurodegenerative disorders such as AD. American Chemical Society 2020-06-04 /pmc/articles/PMC7301577/ /pubmed/32566864 http://dx.doi.org/10.1021/acsomega.0c01381 Text en Copyright © 2020 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Hira, Sundas
Saleem, Uzma
Anwar, Fareeha
Raza, Zohaib
Rehman, Atta Ur
Ahmad, Bashir
In Silico Study and Pharmacological Evaluation of Eplerinone as an Anti-Alzheimer’s Drug in STZ-Induced Alzheimer’s Disease Model
title In Silico Study and Pharmacological Evaluation of Eplerinone as an Anti-Alzheimer’s Drug in STZ-Induced Alzheimer’s Disease Model
title_full In Silico Study and Pharmacological Evaluation of Eplerinone as an Anti-Alzheimer’s Drug in STZ-Induced Alzheimer’s Disease Model
title_fullStr In Silico Study and Pharmacological Evaluation of Eplerinone as an Anti-Alzheimer’s Drug in STZ-Induced Alzheimer’s Disease Model
title_full_unstemmed In Silico Study and Pharmacological Evaluation of Eplerinone as an Anti-Alzheimer’s Drug in STZ-Induced Alzheimer’s Disease Model
title_short In Silico Study and Pharmacological Evaluation of Eplerinone as an Anti-Alzheimer’s Drug in STZ-Induced Alzheimer’s Disease Model
title_sort in silico study and pharmacological evaluation of eplerinone as an anti-alzheimer’s drug in stz-induced alzheimer’s disease model
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301577/
https://www.ncbi.nlm.nih.gov/pubmed/32566864
http://dx.doi.org/10.1021/acsomega.0c01381
work_keys_str_mv AT hirasundas insilicostudyandpharmacologicalevaluationofeplerinoneasanantialzheimersdruginstzinducedalzheimersdiseasemodel
AT saleemuzma insilicostudyandpharmacologicalevaluationofeplerinoneasanantialzheimersdruginstzinducedalzheimersdiseasemodel
AT anwarfareeha insilicostudyandpharmacologicalevaluationofeplerinoneasanantialzheimersdruginstzinducedalzheimersdiseasemodel
AT razazohaib insilicostudyandpharmacologicalevaluationofeplerinoneasanantialzheimersdruginstzinducedalzheimersdiseasemodel
AT rehmanattaur insilicostudyandpharmacologicalevaluationofeplerinoneasanantialzheimersdruginstzinducedalzheimersdiseasemodel
AT ahmadbashir insilicostudyandpharmacologicalevaluationofeplerinoneasanantialzheimersdruginstzinducedalzheimersdiseasemodel